Biostax Corp.

Equities

BTAX

US45252A3059

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:34:21 2024-07-03 am EDT			5-day change	1st Jan Change
0.0598 ^USD	+19.72%		+43.41%	-18.08%

May. 20	Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Immune Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 24, 2021 at 03:24 pm EDT

Immune Therapeutics, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 287,419 compared to USD 395,305 a year ago. Net income was USD 790,407 compared to net loss of USD 792,873 a year ago.

Latest news about Biostax Corp.

Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 20	CI
Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Biostax Corp. Appoints Craig Suro as a Director	Nov. 15	CI
Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Biostax Corp. Appoints Mary Clay Caperton to its Board of Directors	Nov. 02	CI
Immune Therapeutics, Inc. will Change its Name to Biostax Corp	23-10-05	CI
Immune Therapeutics, Inc. Announces CEO Changes	23-09-13	CI
Immune Therapeutics, Inc. Announces Management Changes	23-09-13	CI
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV	23-08-29	CI
Immune Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Immune Therapeutics, Inc. Announces the Fdas Acceptance of Three Investigational New Drug Applications Transfers for Jkb-122 for the Treatment of Nash, Nafld and Aih	23-08-15	CI
Biostax Corp. announced that it expects to receive $12 million in funding from DealBox, Inc	23-05-29	CI
DealBox, Inc announced that it has received $12 million in funding from Immune Therapeutics, Inc.	23-05-29	CI
Immune Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Immune Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-10	CI
Immune Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-04-09	CI
Immune Therapeutics, Inc. Announces Director Resignations	23-01-03	CI
Immune Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Immune Therapeutics, Inc. Announces Executive Changes	22-11-09	CI
Immune Therapeutics, Inc. Announces CEO Changes	22-11-09	CI
Immune Therapeutics, Inc. Appoints H. Louis Salomonksy to Its Board of Directors	22-09-27	CI
Immune Therapeutics, Inc. announced a financing transaction	22-08-30	CI
Immune Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-24	CI
Immune Therapeutics, Inc. Announces the Appointment of Glen Farmer as Chief Financial Officer	22-08-04	CI
Immune Therapeutics, Inc. Announces the Appointment of Kelly O’Brien Wilson as Chief Operating Officer	22-08-04	CI

Chart Biostax Corp.

Duration

Period

More charts

Company Profile

Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOSTAX CORP.	-18.08%	5.01M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B
ARGENX SE	+18.63%	25.98B
BIONTECH SE	-24.33%	19.27B
GENMAB A/S	-18.38%	15.99B
BEIGENE, LTD.	-17.95%	15.66B
WUXI APPTEC CO., LTD.	-48.32%	14.5B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B

Bio Therapeutic Drugs